Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Geoffrois

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2016
Long-term update of the 24954 EORTC phase III trial on larynx preservationB Henriques De Figueiredo, C Fortpied, J Menis, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Gimel, M Gross-Goupil, L Geoffrois, et al.
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2014
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II studyF Selle, S Wittnebel, P Biron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2016
Long-term update of the 24954 EORTC phase III trial on larynx preservationB Henriques De Figueiredo, C Fortpied, J Menis, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 14, 2015
[Not Available]P Gimel, M Gross-Goupil, L Geoffrois, et al.
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCCJ J Knox, C H Barrios, T M Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2014
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II studyF Selle, S Wittnebel, P Biron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Pageof 4